Business
Sareum to Present at BIO Digital 2020
Sareum to Present at BIO Digital 2020.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n RNS Number : 9855N\n Sareum Holdings PLC\n 27 May 2020\n \n \n \n \n 27 May 2020\n \n \n Sareum Holdings PLC\n \n \n (\"Sareum\" or the \"Company\")\n \n \n Sareum to Present at BIO Digital 2020\n \n \n Sareum Holdings plc (AIM:SAR)\n , the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases\n , announces that its CEO, Dr Tim Mitchell, will give a Company presentation at BIO Digital 2020, which will be delivered on-line from 8-12 June 2020. \n \n \n The presentation will highlight Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes, SDC-1801 and SDC-1802, targeting autoimmune diseases and cancers, respectively. Dr Mitchell will also outline the emerging potential of this mechanism to modulate the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections.\n \n \n The presentation will be made through the BIO Digital website and will be available on demand to registered participants during the conference - \n \n www.bio.org/events/bio-digital/sessions/685707\n \n .\n \n \n A copy of the presentation will also be made available on Sareum's website - \n \n www.sareum.co.uk\n \n . The Company's website has also been updated to include information on the potential of its SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19 - \n \n www.sareum.com/discovery/tyk2jak1-covid19/\n \n .\n \n For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources to help drive participant's businesses, and the insights needed to continue critical research and development.\n \n For further information, please contact: \n \n \n Sareum Holdings plc\n \n \n Tim Mitchell, CEO 01223 497 700\n \n \n Strand Hanson Limited (Nominated Adviser)\n \n \n James Dance / Richard Tulloch 020 7409 3494\n \n \n Hybridan LLP (Nominated Broker)\n \n \n Claire Noyce / John Beresford-Peirse &n...